On August 22, 2024, ARCA stockholders approved a merger with Oruka, which took effect on August 29, 2024. As a result of the merger and concurrent name change, former ARCA stockholders became stockholders of Oruka. Concurrent with the merger, the company underwent a 1 for 12 reverse stock split, which had the effect of dividing the number of shares held by each stockholder by 12 (and notionally increasing the price per share by 12x). If the reverse stock split resulted in ownership of a fraction of a share, that fraction was converted to cash. For more information please view our SEC filings HERE.

For ABIO stockholders as of March 4, 2013, the attached IRS Form 8937 – 3.4.2013 provides details to assist you with calculating the cost basis of your investment and tax impact of any fractional share payments for tax purposes.

For ABIO stockholders as of September 3, 2015, the attached IRS Form 8937 – 9.3.2015 provides details to assist you with calculating the cost basis of your investment and tax impact of any fractional share payments for tax purposes.

For ABIO stockholders as of April 3, 2019, the attached IRS Form 8937 – 4.3.2019 provides details to assist you with calculating the cost basis of your investment and tax impact of any fractional share payments for tax purposes.

For ABIO stockholders as of August 26, 2024, the attached IRS Form 8937 – 8.6.24 provides details to assist you with calculating the cost basis of your investment and tax impact of special dividend for tax purposes.

For Oruka stockholders as of September 3, 2024, the attached IRS Form 8937 – 9.3.24 provides details to assist you with calculating the cost basis of your investment and tax impact of any fractional share payments for tax purposes.

Oruka Therapeutics’ SEC filings can be viewed on our SEC Filings page or at SEC.gov (search for Oruka Therapeutics, Inc., the “ORKA” company ticker, or for CIK: 0000907654).

You can submit inquiries to Oruka Therapeutics’ investor relations department by contacting ir@orukatx.com.